NeuroSense Therapeutics & Massachusetts General Hospital’s NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS
NeuroSense Therapeutics, a company developing treatments for severe neurodegenerative diseases, today announced it has signed a collaboration agreement with Dr Ghazaleh Sadri-Vakili, MS, PhD and Massachusetts General Hospital’s NeuroEpigenetics Lab to explore the neurotherapeutic effects of its lead combination drug, PrimeC, utilizing a novel in vitro model generated from post-mortem ALS brain tissue (synaptoneurosomes (SNs) system).
Dr. Sadri-Vakili, Associate Professor at Harvard Medical School and the Director of the NeuroEpigenetics laboratory at the MassGeneral Institute for Neurodegenerative Disease, focuses on understanding the mechanisms involved in neurological disorders. Dr. Sadri-Vakili’s laboratory has identified disease specific alterations in multiple cellular pathways using human samples as well as cellular and animal models of amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), and X-linked dystonia-parkinsonism (XDP). In ALS, the laboratory is assessing the pathogenic role of neuroinflammation and oxidative stress using post-mortem samples. Key elements of these studies have recently been published using a novel ALS SNs system.
The objective of the collaborative studies is to expand the understanding of PrimeC’s mechanism of action in attenuating ALS-related pathology, specifically TDP-43 accumulation, autophagy defects, mitochondrial dysfunction, and oxidative stress. To address this, ALS- or control-SNs derived from post-mortem brains will be used to treat SH-SY5Y cells to induce reactive oxygen species and mitochondrial dysfunction, as previously shown by the Sadri-Vakili lab, in the presence or absence of PrimeC. Importantly, the studies will compare the potential therapeutic effect of PrimeC combination therapy relative to each one of its FDA-approved compounds, ciprofloxacin and celecoxib, separately, to further demonstrate the beneficial synergistic effect of PrimeC as a combination therapy.
“We are excited to join NeuroSense in its mission to advance PrimeC for people living with ALS,” commented Dr. Sadri-Vakili. “Our laboratory prides itself on partnering with industry collaborators to assess the neuroprotective efficacy of new treatments with the hopes of identifying novel therapies for ALS. Our in vitro model may serve as an effective tool to increase our understanding of PrimeC’s neurotherapeutic mechanism of action.”
NeuroSense’s Vice President of R&D, Dr. Shiran Zimri stated, “Having worked closely with Massachusetts General Hospital on our biomarker studies, we are pleased to formally establish this important collaboration with Dr. Sadri-Vakili’s team, where we hope to elucidate PrimeC’s efficacy via key measurements that correlate with our Phase 2b ALS study endpoints.”
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more